ArticleAmerican journal of translational research2025
Role of the TLR2/NF-κB signaling pathway and the aggregate index of systemic inflammation as prognostic indicators in papillary thyroid carcinoma.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the expression of the TLR2/NF-κB signaling pathway and the Aggregate Index of Systemic Inflammation (AISI) in patients with papillary thyroid carcinoma (PTC) and to evaluate their clinical relevance to prognosis.
methodsIn this retrospective study, we analyzed surgically resected tumor tissue samples from 273 patients with PTC (PTC group) and paired adjacent non-tumorous tissues (PT group), as well as 104 nodular goiter tissues (NG group). The AISI values, along with the positive rates and mRNA expression levels of TLR2, MyD88, and NF-κB, were compared among the three groups. Differences in these indicators were compared across PTC patients with different clinicopathologic features. All PTC patients were followed up for three years and categorized into a survival group (n = 70) and a death group (n = 203) based on prognosis, and between-group comparisons were performed. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the prognostic performance of each indicator. Kaplan-Meier survival curves were generated to compare overall survival between high- and low-expression subgroups stratified by TLR2, MyD88, NF-κB mRNA and AISI levels. Cox regression analysis was conducted to identify independent prognostic factors in PTC.
resultsCompared to the NG and PT groups, the PTC group showed higher AISI values, and protein positivity and mRNA expression of TLR2, MyD88, and NF-κB (all P<0.05). In the PTC group, the expression levels of these biomarkers and AISI values differed significantly according to tumor stage, lymph node metastasis, degree of differentiation, and extraglandular extension (P<0.05). Significant differences in differentiation grade, lymph node metastasis, extrathyroidal extension, TLR2, MyD88, NF-κB mRNA, and AISI levels were observed between the survival and death groups (P<0.05). The AUC values for predicting patient prognosis based on TLR2, MyD88, NF-κB mRNA, and AISI individually or in combination were 0.802, 0.795, 0.799, 0.815, and 0.818, respectively. Patients with low expression levels of TLR2, MyD88, NF-κB mRNA, and AISI had significantly longer overall survival compared to those with high expression levels (P<0.05).
conclusionPoor differentiation, extrathyroidal extension, and high AISI expression are independent factors for poor PTC prognosis. The TLR2/NF-κB signaling pathway and AISI are closely associated with tumor progression and have prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.